Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
View Patent ↗The present invention relates to compounds of the general formula: (I) wherein ring B, R 1 , R 2 , R 3 , Z, and L 1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
1. A compound, or a pharmaceutically acceptable salt thereof, said compound having the general structure shown in Formula (V):
wherein R 1 , R 2 , R 3 , L 1 , and Z are selected independently of each other and wherein:
q is 0 and R a is absent;
L 1 is selected from the group consisting of —S(O) 2 —, —C(O)—, —C(O)NH—, —(CH(CH 3 ))—, and —CH 2 —;
R 1 is selected from the group consisting of phenyl and naphthyl,
wherein said phenyl and said naphthyl are substituted with from 1 to 3 groups each independently selected from:
halo, haloalkyl, alkoxy, and haloalkoxy;
R 2 is phenyl,
wherein said phenyl is substituted with from 1 to 3 groups each independently selected from:
halo, haloalkyl, alkoxy, and haloalkoxy;
R 3 is selected from the group consisting of H and lower alkyl; and
Z is selected from the group consisting of: —(CH 2 )—(CH(CH 3 ))—C(O)OH, —(CH 2 )—(CH 2 )—(CH 2 )—C(O)OH, —(CH 2 )—C(CH 3 ) 2 —C(O)OH, —(CH 2 )—C(CH 3 )(OH)—C(O)OH, —CH 2 —CH 2 —C(O)OH, —CH 2 —CH(OH)—C(O)OH, —CH(CH 3 )—CH 2 —C(O)OH, —CH 2 —CH(F)—C(O)OH, —CH 2 —CF 2 —C(O)OH, —CH(CH 3 )—CF 2 —C(O)OH, and —CH 2 —CH 2 —CF 2 —C(O)OH.
2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of H and methyl.
3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is naphthyl,
wherein said naphthyl is substituted with from 1 to 3 groups each independently selected from:
—Cl, —F, —CF 3 , —O—CH 3 , and —OCF 3 .
4. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is
and R 2 is
5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —CH 2 —CH 2 —C(O)OH.
6. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 3 is H.
7. A compound, or a pharmaceutically acceptable salt thereof, said compound which is:
Example
Compound
1
Ex. 1
2
Ex. 2
3
Ex. 3
4
Ex. 4 isomer A
5
Ex. 5 isomer B
6
Ex. 6 isomer A
7
Ex. 7 isomer A
8
Ex. 8 isomer B
9
Ex. 9
10
Ex. 10
11
Ex. 11
12
Ex. 12 isomer A
13
Ex. 13 isomer B
8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition according to claim 8 , further comprising at least one other antidiabetic agent.
10. A pharmaceutical composition according to claim 9 , wherein said at least one other antidiabetic agent is: a DPP-IV inhibitor, an insulin sensitizer, insulin, an insulin mimetic, an insulin secretagogue, a glucosidase inhibitor, an alpha glucosidase inhibitor, a glucagon receptor antagonist, glucophage, glucophage XR, an antihypertensive agent, a meglitinide, an alpha-glucosidase inhibitor, amlintide, pramlintide, exendin, a histamine H 3 receptor antagonist, dapagliflozin, sergliflozin, AVE2268 (Sanofi-Aventis) and T-1095 (Tanabe Seiyaku), a cholesterol lowering agent, a PACAP, a PACAP mimetic, a PACAP receptor 3 agonist, a PPAR delta agonist, an antiobesity agent, an ileal bile acid transporter inhibitor, an NSAID, a CB1 receptor antagonist, or a CB1 receptor inverse agonist.
11. A method for treating or delaying the onset of type 2 diabetes mellitus in a patient in need thereof comprising administering to said patient a compound of claim 1 in an amount that is effective to treat type 2 diabetes mellitus.